Bernhard Zimmermann,
Vice President of Research and Development
Bernhard Zimmermann has been a pioneer in the field of cell-free DNA for 20 years. At Natera he was the lead scientist in the development of massively multiplex PCR and the market-leading Panorama non-invasive prenatal test (NIPT). More recently, his team has developed multiple workflows for analysis of circulating tumor DNA using fixed and personalized panels. Results of this work were published in a cover article of Nature with the title “Phylogenetic ctDNA analysis depicts early stage lung cancer evolution”. In August 2017 Natera launched the personalized Liquid Biopsy test, Signatera, for research use only.
|
|
|
